Start-ups floated faster than usual in 2020, a new analysis finds. For a deeper look at biopharma deal trends, our free report is available to download today.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
The German group hopes that boosting its presence in gene therapy will drive growth of its pharma business.
Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.